[Schnitzler syndrome: A review of literature, the authors' observation, and experience with the interleukin-1 inhibitor canakinumab]

Ter Arkh. 2017;89(11):111-115. doi: 10.17116/terarkh20178911111-115.
[Article in Russian]

Abstract

The paper reviews the publications dealing with Schnitzler syndrome, a rare autoinflammatory disease, and describes the authors' own clinical observation. It describes the first Russian experience in successfully using the interleukin-1 inhibitor canakinumab to treat this disease.

В статье представлен обзор публикаций, посвященных редкому аутовоспалительному синдрому Шнитцлера, приведено описание собственного наблюдения в клинической практике. Отражен первый российский опыт успешного применения ингибитора интерлейкина-1 канакинумаба при этом заболевании.

Keywords: IL-1 inhibitors; Schnitzler syndrome; autoinflammatory diseases; canakinumab; therapy.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Immunologic Factors / pharmacology*
  • Interleukin-1 / antagonists & inhibitors*
  • Schnitzler Syndrome / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Interleukin-1
  • canakinumab